ProSomnus Sleep Technologies, Inc.
Pleasanton, United States · 140 employees
ProSomnus (NASDAQ: OSA) is a leading CPAP alternative for the treatment of Obstructive Sleep Apnea, a serious medical disease affecting over 1 billion people worldwide, that is associated with comorbidities including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each
Funding history
- Corporate Round — $38.0M — Feb 2026
- Venture - Series Unknown — $10.1M — Oct 2023
- Funding Round — $10.0M — Sep 2023
- Pre-Seed — $50K — Aug 2019
Recent signals
- Jun 19, 2026: ProSomnus collaborates with MonitAir to enhance sleep apnea monitoring through digital integration.
- Feb 18, 2026: Raised $38.0M in Corporate Round
- Oct 02, 2023: Raised $10.1M in Venture - Series Unknown
- Sep 21, 2023: Raised $10.0M in Funding Round
- Aug 20, 2019: Raised $50K in Pre-Seed
See plans & pricing → Track ProSomnus Sleep Technologies, Inc.’s funding, hiring, and signals — with verified contacts — on Fundz.